Zoetis Inc

NYSE ZTS

Data sourced from

and

Download Data

Zoetis Inc Working Capital to Current Liabilities Ratio 5 year CAGR for the year ending December 31, 2023: -1.91%

Zoetis Inc Working Capital to Current Liabilities Ratio 5 year CAGR is -1.91% for the year ending December 31, 2023, a 85.99% change year over year. The working capital to current liabilities ratio measures the proportion of working capital to current liabilities. It is calculated by dividing the difference between current assets and current liabilities by current liabilities. This ratio indicates the company's ability to cover its current liabilities with its working capital. A higher ratio suggests a healthier liquidity position and better ability to meet short-term obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Zoetis Inc Working Capital to Current Liabilities Ratio for the year ending December 31, 2022 was 1.37, a -52.04% change year over year.
Zoetis Inc Working Capital to Current Liabilities Ratio for the year ending December 31, 2021 was 2.86, a 39.57% change year over year.
Zoetis Inc Working Capital to Current Liabilities Ratio for the year ending December 31, 2020 was 2.05, a 25.63% change year over year.
Zoetis Inc Working Capital to Current Liabilities Ratio for the year ending December 31, 2019 was 1.63, a -37.27% change year over year.

NYSE: ZTS

Zoetis Inc

CEO	Ms. Kristin C. Peck
IPO Date	Feb. 1, 2013
Location	United States
Headquarters	10 Sylvan Way, Parsippany, NJ, United States, 07054
Employees	14,100
Sector	Healthcare
Industry	Drug manufacturers - specialty & generic

Description

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Key trends